• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

人La蛋白：一种参与卵巢癌发展和多药耐药的RNA结合蛋白。

Human La Protein: An RNA-Binding Protein Involved in Ovarian Cancer Development and Multidrug Resistance.

作者信息

Huang Xuan, Tang Jing

机构信息

Department of Pharmacy, Obstetrics & Gynecology Hospital of Fudan University, Shanghai 200011, People's Republic of China.

出版信息

Onco Targets Ther. 2020 Oct 22;13:10721-10727. doi: 10.2147/OTT.S269983. eCollection 2020.

DOI:10.2147/OTT.S269983
PMID:33132701
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7592153/
Abstract

Multidrug resistance is the main cause of chemotherapy failure and death in patients with advanced ovarian cancer. Drug resistance is a problem that must be solved to improve the survival rate of patients with advanced ovarian cancer. The RNA-binding protein La and the La-related protein family are highly expressed in various malignant tumors, including ovarian cancer. This article reviews the mechanisms of La protein in tumorigenesis, development, and drug resistance. High La protein expression in tumor cells promotes tumor proliferation, invasion, and migration; disrupts cell cycle; and inhibits tumor cell apoptosis caused by chemotherapeutic drugs through various pathways, resulting in chemotherapy resistance in ovarian cancer. Further study of the role of La protein in ovarian cancer multidrug resistance may be conducive to the development of human La protein-specific inhibitors that suppress ovarian cancer drug resistance.

摘要

多药耐药是晚期卵巢癌患者化疗失败和死亡的主要原因。耐药性是提高晚期卵巢癌患者生存率必须解决的问题。RNA结合蛋白La及La相关蛋白家族在包括卵巢癌在内的多种恶性肿瘤中高表达。本文综述了La蛋白在肿瘤发生、发展及耐药中的作用机制。肿瘤细胞中高表达的La蛋白通过多种途径促进肿瘤增殖、侵袭和迁移；扰乱细胞周期；抑制化疗药物引起的肿瘤细胞凋亡，导致卵巢癌化疗耐药。进一步研究La蛋白在卵巢癌多药耐药中的作用可能有助于开发抑制卵巢癌耐药的人La蛋白特异性抑制剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5529/7592153/ddf91612fae7/OTT-13-10721-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5529/7592153/dcd2fc5367e6/OTT-13-10721-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5529/7592153/ddf91612fae7/OTT-13-10721-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5529/7592153/dcd2fc5367e6/OTT-13-10721-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5529/7592153/ddf91612fae7/OTT-13-10721-g0002.jpg

相似文献

1
Human La Protein: An RNA-Binding Protein Involved in Ovarian Cancer Development and Multidrug Resistance.人La蛋白：一种参与卵巢癌发展和多药耐药的RNA结合蛋白。
Onco Targets Ther. 2020 Oct 22;13:10721-10727. doi: 10.2147/OTT.S269983. eCollection 2020.
2
La protein regulates protein expression by binding with the mRNAs of target genes and participates the pathological process of ovarian cancer.该蛋白通过与靶基因的mRNA结合来调节蛋白表达，并参与卵巢癌的病理过程。
Front Oncol. 2022 Aug 30;12:763480. doi: 10.3389/fonc.2022.763480. eCollection 2022.
3
Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells.腹水增加卵巢癌细胞中多药耐药蛋白的表达/功能。
PLoS One. 2015 Jul 6;10(7):e0131579. doi: 10.1371/journal.pone.0131579. eCollection 2015.
4
Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.含金刚烷胺的铂（IV）配合物克服卵巢癌细胞对顺铂的内在耐药性。
Gynecol Oncol. 2006 Jul;102(1):32-40. doi: 10.1016/j.ygyno.2005.11.016. Epub 2005 Dec 20.
5
MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.微小 RNA-199a 通过靶向 CD44 抑制卵巢癌起始细胞的致瘤性和多药耐药性。
FEBS J. 2012 Jun;279(11):2047-59. doi: 10.1111/j.1742-4658.2012.08589.x. Epub 2012 Apr 24.
6
XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.用小干扰 RNA 下调 XIAP 基因抑制卵巢癌细胞增殖，诱导细胞凋亡，并逆转顺铂耐药性。
Eur J Obstet Gynecol Reprod Biol. 2009 Oct;146(2):222-6. doi: 10.1016/j.ejogrb.2009.06.011. Epub 2009 Sep 15.
7
Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.自噬相关 p62（SQSTM1）在多药耐药性卵巢癌中的表达及作用。
Gynecol Oncol. 2018 Jul;150(1):143-150. doi: 10.1016/j.ygyno.2018.04.557. Epub 2018 Apr 24.
8
Lipoic acid decreases Mcl-1, Bcl-xL and up regulates Bim on ovarian carcinoma cells leading to cell death.硫辛酸可降低卵巢癌细胞中Mcl-1、Bcl-xL的表达，并上调Bim的表达，从而导致细胞死亡。
J Ovarian Res. 2015 Jun 12;8:36. doi: 10.1186/s13048-015-0165-z.
9
PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer.载多柔比星和 BCL2 短发夹 RNA 的 PLGA 纳米粒共递送系统克服复发性或晚期卵巢癌紫杉醇和顺铂耐药。
Sci Rep. 2018 May 14;8(1):7498. doi: 10.1038/s41598-018-25930-7.
10
Assessment of 99mTc-MIBI SPECT(/CT) to monitor multidrug resistance-related proteins and apoptosis-related proteins in patients with ovarian cancer: a preliminary study.99mTc-MIBI SPECT(/CT)评估卵巢癌患者多药耐药相关蛋白和凋亡相关蛋白：一项初步研究
Ann Nucl Med. 2015 Aug;29(7):643-9. doi: 10.1007/s12149-015-0980-8. Epub 2015 Apr 29.

引用本文的文献

1
Unravelling driver genes as potential therapeutic targets in ovarian cancer via integrated bioinformatics approach.通过综合生物信息学方法揭示驱动基因作为卵巢癌潜在治疗靶点
J Ovarian Res. 2024 Apr 23;17(1):86. doi: 10.1186/s13048-024-01402-7.
2
Upregulated SSB Is Involved in Hepatocellular Carcinoma Progression and Metastasis through the Epithelial-Mesenchymal Transition, Antiapoptosis, and Altered ROS Level Pathway.上调的 SSB 通过上皮-间充质转化、抗细胞凋亡和改变 ROS 水平途径参与肝癌的进展和转移。
Oxid Med Cell Longev. 2023 Feb 4;2023:5207431. doi: 10.1155/2023/5207431. eCollection 2023.
3
La protein regulates protein expression by binding with the mRNAs of target genes and participates the pathological process of ovarian cancer.

本文引用的文献

1
Are Wnt/β-Catenin and PI3K/AKT/mTORC1 Distinct Pathways in Colorectal Cancer?Wnt/β-连环蛋白和 PI3K/AKT/mTORC1 是否为结直肠癌中的不同通路？
Cell Mol Gastroenterol Hepatol. 2020;10(3):491-506. doi: 10.1016/j.jcmgh.2020.04.007. Epub 2020 Apr 22.
2
AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells.AXL 靶向治疗可阻断耐药性癌细胞的自噬通量并诱导免疫原性细胞死亡。
J Thorac Oncol. 2020 Jun;15(6):973-999. doi: 10.1016/j.jtho.2020.01.015. Epub 2020 Feb 1.
3
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
该蛋白通过与靶基因的mRNA结合来调节蛋白表达，并参与卵巢癌的病理过程。
Front Oncol. 2022 Aug 30;12:763480. doi: 10.3389/fonc.2022.763480. eCollection 2022.
4
Dacomitinib improves chemosensitivity of cisplatin-resistant human ovarian cancer cells.达可替尼可提高顺铂耐药的人卵巢癌细胞的化疗敏感性。
Oncol Lett. 2021 Jul;22(1):569. doi: 10.3892/ol.2021.12830. Epub 2021 May 29.
奥拉帕利作为 BRCA1-2 突变的复发性铂类敏感卵巢癌患者的维持治疗：真实世界数据和进展后结局。
Gynecol Oncol. 2020 Jan;156(1):38-44. doi: 10.1016/j.ygyno.2019.10.023. Epub 2019 Nov 4.
4
Multidrug resistance affects the prognosis of primary epithelial ovarian cancer.多药耐药影响原发性上皮性卵巢癌的预后。
Oncol Lett. 2019 Oct;18(4):4262-4269. doi: 10.3892/ol.2019.10745. Epub 2019 Aug 14.
5
Diverse mechanisms of PARP inhibitor resistance in ovarian cancer.卵巢癌中PARP抑制剂耐药的多种机制。
Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2):188307. doi: 10.1016/j.bbcan.2019.08.002. Epub 2019 Aug 2.
6
Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer.X连锁凋亡抑制蛋白的抑制作用可增加卵巢癌对卡铂的敏感性。
Onco Targets Ther. 2018 Dec 5;11:8751-8759. doi: 10.2147/OTT.S171053. eCollection 2018.
7
An interdomain bridge influences RNA binding of the human La protein.域间桥影响人 La 蛋白的 RNA 结合。
J Biol Chem. 2019 Feb 1;294(5):1529-1540. doi: 10.1074/jbc.RA118.003995. Epub 2018 Dec 10.
8
Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.细胞周期蛋白 D1 沉默可损害 DNA 双链断裂修复，使 BRCA1 野生型卵巢癌细胞对奥拉帕利敏感。
Gynecol Oncol. 2019 Jan;152(1):157-165. doi: 10.1016/j.ygyno.2018.10.027. Epub 2018 Nov 7.
9
Ovarian cancer stem cell: A potential therapeutic target for overcoming multidrug resistance.卵巢癌干细胞：克服多药耐药性的潜在治疗靶点。
J Cell Physiol. 2019 Apr;234(4):3238-3253. doi: 10.1002/jcp.26768. Epub 2018 Oct 14.
10
PRR11 Overexpression Facilitates Ovarian Carcinoma Cell Proliferation, Migration, and Invasion Through Activation of the PI3K/AKT/β-Catenin Pathway.PRR11过表达通过激活PI3K/AKT/β-连环蛋白通路促进卵巢癌细胞的增殖、迁移和侵袭。
Cell Physiol Biochem. 2018;49(2):696-705. doi: 10.1159/000493034. Epub 2018 Aug 30.